Daiichi Sankyo
LEI 353800XGIU2IHQGC9504
Discover what you can do with Cbonds
Everything you need for fixed income research and monitoring.
- 00:23 Coverage
- 00:40 Bond screener
- 00:54 Parameters
- 01:10 Watchlist, Mobile app
- 01:15 Excel Add-in
Trading Schedule Issuer map
Quotes
- «
- 1
- ...
- {{ quotes.page - 2 }}
- {{ quotes.page - 1 }}
- {{ quotes.page }}
- {{ quotes.page + 1 }}
- {{ quotes.page + 2 }}
- ...
- {{ quotesLastPage }}
- »
Profile
|
Daiichi Sankyo Company, Limited (第一三共株式会社 Daiichi Sankyō Kabushiki-kaisha?) is a global pharmaceutical company and the second largest pharmaceutical company in Japan. It achieved JPY 1,148.2 billion in revenue in 2013. The company owns the American biotechnology company Plexxikon, the German biotechnology company U3 Pharma and recently sold Ranbaxy Laboratories in India. Daiichi Sankyo Co., Ltd. is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen.
|
General information
-
Organization nameDaiichi Sankyo Company, Limited
-
Organization statusOperating organization
-
Address3-5-1, Nihonbashi-honcho Chuo-ku Tokyo, Japan, 103-8426
-
Site
News
| 20/08/2025 | Upcoming Issue: Daiichi Sankyo 1Y |
| 20/08/2025 | Upcoming Issue: Daiichi Sankyo 7Y |
| 20/08/2025 | Upcoming Issue: Daiichi Sankyo 5Y |
| 20/08/2025 | Upcoming Issue: Daiichi Sankyo 3Y |
| 31/01/2025 | Daiichi Sankyo's Nine-Month Profit Jumps 28% |
Stocks
General information
-
Organization nameDaiichi Sankyo Company, Limited
-
Organization statusOperating organization
-
Address3-5-1, Nihonbashi-honcho Chuo-ku Tokyo, Japan, 103-8426
-
Site
Codes
-
LEI353800XGIU2IHQGC9504
-
SIC2834 PHARMACEUTICAL PREPARATIONS
-
NACE*** ***
-
NAICS*** ***
-
CIK0001340156









